JP7642540B2 - Ｃ－ｊｕｎ－ｎ末キナーゼのピラゾロピリジンインヒビターおよびそれらの使用 - Google Patents

Ｃ－ｊｕｎ－ｎ末キナーゼのピラゾロピリジンインヒビターおよびそれらの使用 Download PDF

Info

Publication number
JP7642540B2
JP7642540B2 JP2021533779A JP2021533779A JP7642540B2 JP 7642540 B2 JP7642540 B2 JP 7642540B2 JP 2021533779 A JP2021533779 A JP 2021533779A JP 2021533779 A JP2021533779 A JP 2021533779A JP 7642540 B2 JP7642540 B2 JP 7642540B2
Authority
JP
Japan
Prior art keywords
optionally substituted
hydrogen
alkyl
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021533779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513846A5 (https=
JP2022513846A (ja
Inventor
グレイ，ナサナエル，エス．
チャン，ティンフー
リュウ，ヤオ
ガオ，ヤン
Original Assignee
ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド filed Critical ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド
Publication of JP2022513846A publication Critical patent/JP2022513846A/ja
Publication of JP2022513846A5 publication Critical patent/JP2022513846A5/ja
Application granted granted Critical
Publication of JP7642540B2 publication Critical patent/JP7642540B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021533779A 2018-12-14 2019-12-13 Ｃ－ｊｕｎ－ｎ末キナーゼのピラゾロピリジンインヒビターおよびそれらの使用 Active JP7642540B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862780066P 2018-12-14 2018-12-14
US62/780,066 2018-12-14
PCT/US2019/066201 WO2020123925A1 (en) 2018-12-14 2019-12-13 Pyrazolopyridine inhibitors of c-jun-n-terminal kinases and uses thereof

Publications (3)

Publication Number Publication Date
JP2022513846A JP2022513846A (ja) 2022-02-09
JP2022513846A5 JP2022513846A5 (https=) 2022-12-21
JP7642540B2 true JP7642540B2 (ja) 2025-03-10

Family

ID=71077020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021533779A Active JP7642540B2 (ja) 2018-12-14 2019-12-13 Ｃ－ｊｕｎ－ｎ末キナーゼのピラゾロピリジンインヒビターおよびそれらの使用

Country Status (7)

Country Link
US (1) US20220073512A1 (https=)
EP (1) EP3893879A4 (https=)
JP (1) JP7642540B2 (https=)
CN (1) CN113164477A (https=)
AU (1) AU2019395255B2 (https=)
CA (1) CA3115126A1 (https=)
WO (1) WO2020123925A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011090738A2 (en) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
USRE50776E1 (en) 2015-03-27 2026-02-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
AU2017363307B2 (en) * 2016-11-22 2021-07-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
US12281126B2 (en) 2018-12-28 2025-04-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
CA3147422A1 (en) * 2019-07-17 2021-01-21 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CN120661695B (zh) * 2025-06-20 2026-03-20 山东大学齐鲁第二医院 联合上调snrk基因与gsk3b基因表达水平在制备抗非小细胞肺癌药物中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007123892A2 (en) 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
US20110039873A1 (en) 2009-06-08 2011-02-17 Gaeta Federico C A SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP2014533695A (ja) 2011-11-17 2014-12-15 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
US20160264551A1 (en) 2013-10-18 2016-09-15 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
JP2016533379A (ja) 2013-10-18 2016-10-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013011520A2 (pt) * 2010-11-19 2019-09-24 Hoffmann La Roche pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2
TWI621618B (zh) * 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007123892A2 (en) 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
US20110039873A1 (en) 2009-06-08 2011-02-17 Gaeta Federico C A SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
JP2014533695A (ja) 2011-11-17 2014-12-15 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US20160264551A1 (en) 2013-10-18 2016-09-15 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
JP2016533379A (ja) 2013-10-18 2016-10-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤

Also Published As

Publication number Publication date
AU2019395255A1 (en) 2021-05-06
JP2022513846A (ja) 2022-02-09
US20220073512A1 (en) 2022-03-10
WO2020123925A1 (en) 2020-06-18
AU2019395255B2 (en) 2025-02-27
EP3893879A4 (en) 2022-08-17
CA3115126A1 (en) 2020-06-18
CN113164477A (zh) 2021-07-23
EP3893879A1 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
JP7200282B2 (ja) サイクリン依存性キナーゼの阻害剤
JP7642540B2 (ja) Ｃ－ｊｕｎ－ｎ末キナーゼのピラゾロピリジンインヒビターおよびそれらの使用
US20200338075A1 (en) 4,6-pyrimidinylene derivatives and uses thereof
AU2019413694B2 (en) Inhibitors of cyclin-dependent kinase 7 and uses thereof
RU2750164C2 (ru) Цианотиенотриазолодиазепины и пути их применения
AU2020357983B2 (en) Tricyclic kinase inhibitors and uses thereof
AU2020319005B2 (en) Inhibitors of cyclin-dependent kinase 7 and uses thereof
WO2016210291A1 (en) Fused bicyclic pyrimidine derivatives and uses thereof
AU2015335788A1 (en) Thiazolyl-containing compounds for treating proliferative diseases
CA2988330C (en) 4,6-pyrimidinylene derivatives and uses thereof
HK1254654B (en) 4,6-pyrimidinylene derivatives and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240605

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20240722

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240820

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250226

R150 Certificate of patent or registration of utility model

Ref document number: 7642540

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150